Pay in 4 interest-free payments of $5.50 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
While the company did not publicly disclose specific reasons for discontinuation, the lack of statistically significant dose-response at Week 8 in the Phase 2b trial, likely contributed to the decision not to pursue further development in UC
which allows for faster muscle recovery
Our team makes the journey seamless for you, managing the complexity of insurance verification and the prior authorization process, enabling you to prioritize your health and wellness objectives without hassle
Sleep disruption from nighttime pain frequently decreases during this period
The Medicines and Healthcare products Regulatory Agency (MHRA) has not authorised MT-II for human administration, and we make no therapeutic, cosmetic, or health claims about the compound on this page or in any accompanying documentation
neither influenced the content of this publication nor was it involved in the study design, data collection, analysis, interpretation or review
